Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a TDM-guided Clinical Study on the Safety and Efficacy of Mebendazole in Patients With Advanced Gastrointestinal Cancer or Cancer of Unknown Origin

NCT03628079 is registered in ClinicalTrials.gov with Repos Pharma as lead sponsor.

NCT NCT03628079
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03628079 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a TDM-guided Clinical Study on the Safety and Efficacy of Mebendazole in Patients With Advanced Gastrointestinal Cancer or Cancer of Unknown Origin
Lead sponsor
Repos Pharma
Phase
Phase 1/2
Overall status
Terminated
Start date
May 25, 2018
Completion date
January 16, 2019
Enrollment
11 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer of the gastrointestinal tract, cancer of unknown origin